NEFL and myeloid sarcoma: BDNF levels in the CSF at the time of MS diagnosis were inversely associated with cognitive performance in one study; therefore, the authors proposed that BDNF in combination with NfL could be a potential biomarker for impaired cognition in MS but recognize that integration of these measurements into clinical practice could be challenging [90].